Bridge Therapeutics® is an innovative development-stage specialty pharmaceutical company.
Operating as usual
Bridge Therapeutics Names David H. Bergstrom, Ph.D. as Chief Executive Officer
Drug Development Company Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as Chief Executive Officer | Bridge Therapeutics Birmingham, AL – July 19 2021 – Bridge Therapeutics Inc. (Bridge) has promoted David H. Bergstrom, Ph.D. to the position of interim Chief Executive Officer. Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has ove...
Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users
Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users Buprenorphine buccal film may be a safer treatment option than oxycodone among recreational opioid users seeking treatment for chronic pain conditions, an analysis of a phase I trial has found.
“As clinicians and advocates on the frontlines of the addiction and overdose crisis, we call on congressional leaders to confront this epidemic with the urgency and boldness it requires,” the addiction specialty groups wrote to congress.
Opioid Deaths Spark Push to Ease Buprenorphine Rules | Bridge Therapeutics In a Jan. 26 statement, the American Society of Addiction Medicine, the National Council for Behavioral Health and a handful of other addiction advocacy groups urged Congress to eliminate the training requirement as quickly as possible. “As clinicians and advocates on the frontlines of the addicti...
HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles
“The medical evidence is clear: access to medication-assisted treatment, including buprenorphine that can be prescribed in office-based settings, is the gold standard for treating individuals suffering from opioid use disorder,” Adm. Brett P. Giroir, MD
HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles | Bridge Therapeutics The Department of Health & Human Services has issued guidance to do away with the so-called X-waiver, a move the agency said will increase the number of providers able to deliver medication-assisted treatment and therefore increase patient access to care. “The medical evidence is clear: access to ...
“Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs." - Dr. Babul https://tinyurl.com/yxakt3t9
Najib Babul Discusses the Benefits and Limitations of the 505(B)(2) Regulatory Pathway For Drug Approval | Bridge Therapeutics “Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs. In this manner, companies can use the 505(b)(2) regulatory pathway to repurpose or reposition drugs for new indicatio...
Bridge Therapeutics has officially opened its first IND (Investigational New Drug) application with the FDA! https://www.bridgetherapeutics.com/press-releases/investigational-new-drug-ind-application-now-open-bt-219-opioid-dependence/
bridgetherapeutics.com Birmingham, AL – April 27, 2020 – Bridge Therapeutics Inc. heard today from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application No.142396 for the Company’s lead product candidate, BT-219 (Bunalz™) is “Open and Safe to Proceed”. There were no ad...
Bridge Therapeutics has submitted an IND application to the FDA for its lead product candidate BT-219. This is a major step in the development of an additional opioid addiction medication to combat the #opioidcrisis
See our press release:
bridgetherapeutics.com Birmingham, AL – March 25, 2020 – Bridge Therapeutics Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, BT-219 (Bunalz™). BT-219, or Bunalz™, is an investigationa...
bridgetherapeutics.com Recently, analytical assessment of the 1-month stability of Bridge’s BT-219 therapy was completed with satisfactory results. Bridge’s Chief Operating Officer, David H Bergstrom, PhD, commented, “This is a significant milestone in that it demonstrates acceptable product characteristics and thus...
Bridge Therapeutics is pleased to announce it has received FDA feedback on the development of BT-219, a therapy to treat Opioid Dependence.
newswire.com Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months Press Release - updated: Nov 7, 2019 BIRMINGHAM, Ala., November 7, 2019 (Newswire.com) - Bridge Therapeutics Inc. today announced that it has received feedback from the Food ...
Bridge Therapeutics is pleased to announce the addition of Edward Minskoff to our Board of Directors!
newswire.com Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors Press Release - updated: Apr 23, 2019 09:26 CDT BIRMINGHAM, Ala., April 23, 2019 (Newswire.com) - Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy fo...
The evidence for using buprenorphine in the treatment of opioid addiction is overwhelming, yet stigmas and biases still remain leading to inadequate treatment of those battling addiction.
behavioral.net December 21, 2018 by Gary A. Enos, Contributing Editor | Reprints An editorial co-authored by experts at Boston Medical Center and published this week in a primary care journal takes aim at restrictive government regulations and lingering provider biases that hinder access to two of the three approv...
psychcongress.com Buprenorphine-naloxone should be favored over extended-release naltrexone as first-line treatment for opioid use disorder (OUD) in adults, according to a cost-effectiveness analysis.
Steve Passik Ph.D., a recognized leader and researcher in pain management and addiction joins Bridge Therapeutics’ Scientific Advisory Board.
newswire.com Bridge Therapeutics Announces the Addition of Dr. Steve Passik to Its Scientific Advisory Board
As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics' Scientific Advisory Board.
newswire.com Dr. Bob Rappaport joins Bridge Therapeutics' Scientific Advisory Board as its newest member
David O'Gurek, M.D., said stigma is one of the challenges of overcoming substance abuse disorder. He said buprenorphine can help by giving people more control.
aafp.org During a Family Medicine Experience main-stage presentation on opioids, an HHS representative said family physicians can help curb the crisis by prescribing buprenorphine. A panel of family physicians agreed.
Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member.
prnewswire.com BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific...
Bridge Therapeutics is happy to announce the addition of Dr. Jeffrey Fudin to its Scientific Advisory Board. Among other activities and accolades, Dr. Fudin is an active lecturer, writer, and researcher on pain management issues.
Unlike the US, France allows all physicians to prescribe Buprenorphine to treat opioid addiction. Reducing the barriers in the US would allow for more patients to recover using this proven lifesaving treatment.
nbcnews.com Buprenorphine is a treatment for opioid addiction designed to curb cravings and reduce overdoses. France changed the law in the 1990s to allow all practitioners to prescribe it and the cost is covered under the country’s universal health care.
According to an NIH study, adults prescribed Buprenorphine had a decreased mortality rate of 38%, compared with patients not receiving any medication-assisted treatment over the one-year study period.
painmedicinenews.com Treatment of opioid use disorder after a nonfatal opioid overdose with either methadone or buprenorphine is underutilized when compared with each therapy’s proven ability to dramatically reduce mortality rates, according to a study in the Annals of Internal Medicine (2018 Jun 19. [Epu...
In this article, The Washington Examiner discusses the effectiveness of Buprenorphine for treating opioid addiction as well as the red tape that's limiting access to the life saving therapy.
washingtonexaminer.com The Center for Disease Control and Prevention released preliminary overdose estimates for 2017. Although a few states offer some encouraging examples of progress, the estimates — or even just one, the record 72,000 overdose deaths — offer a troubling look at how the United States is still…
In a recent New England Journal of Medicine article, addiction experts Sarah Wakeman MD and Michael Barnett MD, discuss how “to have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get he**in and fentanyl.”
nejm.org Perspective from The New England Journal of Medicine — Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities
In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria.
pbs.org Here is the neuroscience behind how opioids overtake the human brain.
"The opioid crisis gripping communities across the U.S. also is taking an economic toll, Fed Chairman Jerome Powell said.”
bridgetherapeutics.com America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in t...
After a great holiday week, the Bridge Team is gearing up for a series of trips and events as we prepare to release our Chronic Pain Drug Development Program. Please share our page with your family and friends & take a look at our website as we work towards practical solution in ending the Opioid Crisis!
newswire.com Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 youngStartup Ventures Summit in New York Press Release - updated: Jul 9, 2018 11:07 EDT NEW YORK, July 9, 2018 (Newswire.com) - Executives with the innovative late development-stage pharmaceutical....
The Bridge Therapeutics Team traveled to Boston for the BIO International Convention. Bridge met with investors as well as worked to attain other sources of capital. The team, also, met with vendors and service providers in preparation for the launch of their lead investigational drug BT-205. Bridge’s Tim Peara, Alton Kelley, and Dave Bergstrom were a part of the nearly 47,000 partnering meetings that occurred making them a part of the Guinness Book of World Records “Largest Business Partnering Event”.
“We’re really hoping to work with investors on financing so we can get our drug to the FDA,” said Alton Kelley, the firm’s director of business development. “We’re going to need a little more capital to get it through the finish line.
According to the National Institute on Drug Abuse, more than 17,000 people overdosed while using prescription opioids in 2016.
#NationalInstituteonDrugAbuse #OpioidCrisis #TheMoreYoKnow #BridgeTherapeutics #Addiction #DrugAbuse
While U.S. Citizen only make up 5% of the world's population, the U.S. consumes roughly 80% of the world's prescription opioid drugs.
#NationalInstituteonDrugAbuse #OpioidCrisis #TheMoreYoKnow #BridgeTherapeutics #Addiction #DrugAbuse
According to the National Institute on Drug Abuse, 80% of He**in Addicts started by abusing pain medication.
Bridge Therapeutics's cover photo
Bridge Therapeutics is an innovative development-stage specialty pharmaceutical company that is actively researching chronic pain alternatives to help reduce the impact of the opioid epidemic. The pharma company is currently pursuing FDA and European Medicines Agency (EMA) approval of a patented drug combination for the treatment of chronic pain in opioid-experienced patients.
newswire.com Pharmaceutical Startup Bridge Therapeutics Announces New Headquarters in Birmingham, Alabama Press Release - updated: May 16, 2018 BIRMINGHAM, Ala., May 16, 2018 (Newswire.com) - The innovative late development-stage pharmaceutical startup Bridge Therapeutics has announced they will be expandi...
Bridge Therapeutics, Inc. is a development-stage biotech company pursuing FDA approval of a patented drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients.
Our goal is to improve lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.
|Monday||8am - 4pm|
|5pm - 6pm|
|Tuesday||8am - 4pm|
|Wednesday||8am - 4pm|
|Thursday||8am - 4pm|
|Friday||8am - 4pm|
Our mission is to help find a cure for breast cancer by investing in promising research across Alabama and to raise community awareness and funding for that research. Since 1996, we've invested over $11 million in breast cancer research across the state.
A 501c3 public charity that helps men and women live their most beautiful lives in the face of a breast cancer dx by providing access to specialized medical equipment, beauty supplies, and personal care items.
Our mission at Veritas Medical Real Estate is to provide exceptional real estate advisory services to physicians and medical groups based on the core principles of truth, integrity and hard work. We focus on assisting medical practices in making informed
The University of Alabama at Birmingham Spinal Cord Injury Model System is one of 14 national SCI Model Systems programs in the US.
JLF is a non medical health care business we work hard to accommodate our client and family with their every day living
This is the official Facebook account for Samford University's McWhorter School of Pharmacy.
The Alabama Vision Coalition supports access to vision care, education, and research in Alabama
Southern Med Law provides legal representation to victims of harmful drugs, defective medical devices, dangerous products, and other legal claims.
Dr. Blaudeau's first-hand knowledge of Mirena IUD birth defects makes him a powerful legal advocate for women who suffered side effects from Mirena IUDs.